Skip to main content
SpringerLink
Log in

Teriparatide fracture effectiveness in the real world

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bonafede MM, Shi N, Bower AG, Barron RL, Grauer A, Chandler DB (2015) Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis. Osteoporos Int 26:1203–1212. doi:10.1007/s00198-014-2971-3

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  CAS  PubMed  Google Scholar 

  3. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH (2009) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 20:943–948

    Article  CAS  PubMed  Google Scholar 

  4. Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren Ö, Walsh JB, Rajzbaum G, Barker C, Lems WF (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709–2719

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Silverman S, Miller P, Sebba A, Weitz M, Wan X, Alam J, Masica D, Taylor KA, Ruff VA, Krohn K (2013) The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 24:2309–2317

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 23:1103–1113

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

John H. Krege, Russel T. Burge, and Fernando Marin are employees and stockholders of Eli Lilly and Company.

Author information

Authors and Affiliations

  1. Eli Lilly and Company, Lilly Corporate Center, Drop Code 1546, Indianapolis, IN, 46285, USA

    J. H. Krege & R. T. Burge

  2. Lilly Research Centre, Windlesham, UK

    F. Marin

Authors
  1. J. H. Krege
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. T. Burge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Marin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. H. Krege.

Additional information

Dr. Bonafede and colleagues declined the editors’ invitation to provide a response to these comments.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krege, J.H., Burge, R.T. & Marin, F. Teriparatide fracture effectiveness in the real world. Osteoporos Int 26, 2217–2218 (2015). https://doi.org/10.1007/s00198-015-3140-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-015-3140-z

Keywords

Search

Navigation